MAPT and Alzheimer disease: Future directions would further develop this effort to deploy 31P MRS in conjunction with PET-amyloid,-tau, and 18FDG to investigate how abnormal BEM markers modulate the burden of amyloid, tau, and abnormal glucose metabolism in AD neuropathophysiology.